SAN FRANCISCO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a Phase IIIb study in adult patients with early moderate-to-severe erosive rheumatoid arthritis (RA) who had never received previous methotrexate (MTX) treatment. This study showed that ORENCIA® (abatacept) in combination with MTX had significantly more patients achieve a Disease Activity Score 28 using C-reactive protein [DAS28 (CRP)]-defined remission, compared with MTX plus placebo (PBO) (41.4 percent versus 23.3 percent, respectively; p-value less than 0.001). The safety profile of ORENCIA in combination with MTX was similar to that of MTX plus PBO. These results were presented today at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco.
